Apollomics

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on developing oncology therapies that can be combined with other treatments to harness the immune system and target specific molecular pathways to inhibit cancer. The company has built a pipeline of nine drug candidates, six of which are currently in clinical development stages. Apollomics' lead product is vebreltinib (APL-101), a potent and highly selective c-Met inhibitor for treating non-small cell lung cancer and other advanced tumors with c-Met alterations. This drug candidate is currently undergoing a Phase 2 multicohort clinical trial. Another key candidate is uproleselan (APL-106), an E-selectin antagonist with the potential to be used adjunctively with standard chemotherapy for acute myeloid leukemia and other hematologic cancers. Uproleselan is presently in Phase 1 and Phase 3 clinical trials.

In March 2023, Apollomics completed a business combination with Maxpro Capital Acquisition Corp., providing access to capital to advance its pipeline. The company's drug candidates are designed using targeted therapy, immuno-oncology agents, and other innovative approaches to address various cancers, including lung cancer, brain cancer, acute myeloid leukemia, and solid tumors. Apollomics achieved notable milestones in 2022, such as the US FDA granting Orphan Drug Designation to vebreltinib for non-small cell lung cancer and other solid tumors with c-Met dysregulation. The company expects results from its global Phase 2 multicohort trial of vebreltinib this year, potentially supporting its first new drug application with the FDA while generating data on other indications.

In November 2023, Apollomics presented clinical data on vebreltinib's efficacy in treating non-small cell lung cancer with MET exon 14 skipping mutation. The data showed an overall response rate of 75% in patients with locally advanced or metastatic disease. In June 2024, Apollomics announced additional vebreltinib data demonstrating continued efficacy and safety in treating different tumor types carrying MET-driver alterations.